138 related articles for article (PubMed ID: 34393513)
1. The Real-World Practice of Fruquintinib for Chinese Patients with Metastatic Colorectal Cancer.
Song Y; Qu T; Zhang H; Sun Y; Cui C; Chi Y; Zhang W; Wang X; Yang L
Cancer Manag Res; 2021; 13():6199-6205. PubMed ID: 34393513
[TBL] [Abstract][Full Text] [Related]
2. Previous Use of Anti-Vascular Endothelial Growth Factor Receptor Agents Decreases Efficacy of Fruquintinib in Metastatic Colorectal Cancer Refractory to Standard Therapies.
Wang L; Cao H; Jiang C; He W; You Y; Peng K; Jin Y; Xia L
Front Oncol; 2020; 10():587692. PubMed ID: 33282739
[TBL] [Abstract][Full Text] [Related]
3. Safety Profile and Adverse Events of Special Interest for Fruquintinib in Chinese Patients with Previously Treated Metastatic Colorectal Cancer: Analysis of the Phase 3 FRESCO Trial.
Li J; Guo W; Bai Y; Deng Y; Yang L; Chen Z; Zhong H; Xu R; Pan H; Shu Y; Yuan Y; Zhou J; Xu N; Liu T; Ma D; Wu C; Cheng Y; Xu J; Chen D; Li W; Sun S; Yu Z; Cao P; Shen L; Chen H; Wang S; Wang H; Fan S; Guo X; Wang N; Han R; Zhang B; Qin S
Adv Ther; 2020 Nov; 37(11):4585-4598. PubMed ID: 32901330
[TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy of fruquintinib in patients with previously treated metastatic colorectal cancer: a phase Ib study and a randomized double-blind phase II study.
Xu RH; Li J; Bai Y; Xu J; Liu T; Shen L; Wang L; Pan H; Cao J; Zhang D; Fan S; Hua Y; Su W
J Hematol Oncol; 2017 Jan; 10(1):22. PubMed ID: 28103904
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of fruquintinib dose-escalation strategy for elderly patients with refractory metastatic colorectal cancer: A single-arm, multicenter, phase II study.
Tan S; Zhang S; Zhou N; Cai X; Yi C; Gou H
Cancer Med; 2023 Dec; 12(24):22038-22046. PubMed ID: 38063405
[TBL] [Abstract][Full Text] [Related]
6. Efficacy, safety, and predictors of fruquintinib plus anti-programmed death receptor-1 (PD-1) antibody in refractory microsatellite stable metastatic colorectal cancer in a real-world setting: a retrospective cohort study.
Yang X; Yin X; Qu X; Guo G; Zeng Y; Liu W; Jagielski M; Liu Z; Zhou H
J Gastrointest Oncol; 2023 Dec; 14(6):2425-2435. PubMed ID: 38196544
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of toripalimab with fruquintinib in the third-line treatment of refractory advanced metastatic colorectal cancer: results of a single-arm, single-center, prospective, phase II clinical study.
Ma S; Chen R; Duan L; Li C; Yang T; Wang J; Zhao D
J Gastrointest Oncol; 2023 Apr; 14(2):1052-1063. PubMed ID: 37201046
[TBL] [Abstract][Full Text] [Related]
8. A Retrospective Study of Trifluridine/Tipiracil with Fruquintinib in Patients with Chemorefractory Metastatic Colorectal Cancer.
Zou J; Wang Y; Xu J; Li J; Wang T; Zhang Y; Bai Y
J Clin Med; 2023 Dec; 13(1):. PubMed ID: 38202064
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of low-dose apatinib plus S-1 versus regorafenib and fruquintinib for refractory metastatic colorectal cancer: a retrospective cohort study.
Dai Y; Sun L; Zhuang L; Zhang M; Zou Y; Yuan X; Qiu H
J Gastrointest Oncol; 2022 Apr; 13(2):722-731. PubMed ID: 35557597
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the efficacy and safety of fruquintinib and regorafenib in the treatment of metastatic colorectal cancer: A real-world study.
Deng YY; Zhang XY; Zhu PF; Lu HR; Liu Q; Pan SY; Chen ZL; Yang L
Front Oncol; 2023; 13():1097911. PubMed ID: 36937443
[TBL] [Abstract][Full Text] [Related]
11. Real-World Data: Fruquintinib in Treating Metastatic Colorectal Cancer.
Liu S; Lu L; Pan F; Yang C; Liang J; Liu J; Wang J; Shen R; Xin FZ; Zhang N
Oncol Res; 2022 May; 29(1):25-31. PubMed ID: 35063062
[TBL] [Abstract][Full Text] [Related]
12. Fecal microbiota transplantation plus tislelizumab and fruquintinib in refractory microsatellite stable metastatic colorectal cancer: an open-label, single-arm, phase II trial (RENMIN-215).
Zhao W; Lei J; Ke S; Chen Y; Xiao J; Tang Z; Wang L; Ren Y; Alnaggar M; Qiu H; Shi W; Yin L; Chen Y
EClinicalMedicine; 2023 Dec; 66():102315. PubMed ID: 38024475
[TBL] [Abstract][Full Text] [Related]
13. Subgroup Analysis by Liver Metastasis in the FRESCO Trial Comparing Fruquintinib versus Placebo Plus Best Supportive Care in Chinese Patients with Metastatic Colorectal Cancer.
Qin S; Xu RH; Shen L; Xu J; Bai Y; Yang L; Deng Y; Chen ZD; Zhong H; Pan H; Guo W; Shu Y; Yuan Y; Zhou J; Xu N; Liu T; Ma D; Wu C; Cheng Y; Chen D; Li W; Sun S; Yu Z; Cao P; Chen H; Wang J; Wang S; Wang H; Wang N; Zhang B; Zhang Q; Su W; Guo X; Li J
Onco Targets Ther; 2021; 14():4439-4450. PubMed ID: 34408440
[TBL] [Abstract][Full Text] [Related]
14. A multi-center effectiveness comparison study of fruquintinib with constructed external control cohort of other targeted kinase inhibitors using real-world data in third-line treatment of metastatic colorectal cancer.
Jin Y; Li J; Shen L; Xu J; Zhang Y; Zhang J; Pan H; Qu X; Chen Y; Zhang Q; Li J; Sun M; Qin S
Front Oncol; 2022; 12():1044328. PubMed ID: 36505849
[TBL] [Abstract][Full Text] [Related]
15. Fruquintinib in Combination With PD-1 Inhibitors in Patients With Refractory Non-MSI-H/pMMR Metastatic Colorectal Cancer: A Real-World Study in China.
Gou M; Qian N; Zhang Y; Yan H; Si H; Wang Z; Dai G
Front Oncol; 2022; 12():851756. PubMed ID: 35875064
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and Safety Comparison of Regorafenib and Fruquintinib in Metastatic Colorectal Cancer-An Observational Cohort Study in the Real World.
Zhang Q; Chen M; Wang Z; Qi C; Cao Y; Zhang J; Peng Z; Wang X; Lu M; Shen L; Li J
Clin Colorectal Cancer; 2022 Sep; 21(3):e152-e161. PubMed ID: 35216918
[TBL] [Abstract][Full Text] [Related]
17. Subgroup analysis by prior anti-VEGF or anti-EGFR target therapy in FRESCO, a randomized, double-blind, Phase III trial.
Xu R; Qin S; Guo W; Bai Y; Deng Y; Yang L; Chen Z; Zhong H; Pan H; Shu Y; Yuan Y; Zhou J; Xu N; Liu T; Ma D; Wu C; Cheng Y; Xu J; Chen D; Li W; Sun S; Yu Z; Cao P; Li J; Chen H; Wang J; Wang S; Wang H; Wang N; Zhang B; Han R; Su W; Guo X; Li J
Future Oncol; 2021 Apr; 17(11):1339-1350. PubMed ID: 33325251
[TBL] [Abstract][Full Text] [Related]
18. Fruquintinib: a novel antivascular endothelial growth factor receptor tyrosine kinase inhibitor for the treatment of metastatic colorectal cancer.
Zhang Y; Zou JY; Wang Z; Wang Y
Cancer Manag Res; 2019; 11():7787-7803. PubMed ID: 31496821
[TBL] [Abstract][Full Text] [Related]
19. FDA Approval Summary: Fruquintinib for the Treatment of Refractory Metastatic Colorectal Cancer.
Fusco MJ; Casak SJ; Mushti SL; Cheng J; Christmas BJ; Thompson MD; Fu W; Wang H; Yoon M; Yang Y; Moore JN; Bi Y; Nan Y; Long CE; Auth D; Rahman NA; Tang S; Pazdur R; Fashoyin-Aje LA; Kluetz PG; Lemery SJ
Clin Cancer Res; 2024 May; ():. PubMed ID: 38809262
[TBL] [Abstract][Full Text] [Related]
20. Quality-adjusted survival in patients with metastatic colorectal cancer treated with fruquintinib in the FRESCO trial.
Qin S; Li J; Bai Y; Deng Y; Yang L; Xu RH; Zhong H; Chen Z; Pan H; Guo W; Shu Y; Xu J; Peng C; Chen Y; Li H; Wang N; Guo X; Peng M; Fan S; Shen L
Future Oncol; 2021 May; 17(15):1923-1931. PubMed ID: 33563040
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
